EphA2 、VEGF 在非小细胞肺癌中的表达及意义

 目的 探讨Eph受体酪氨酸激酶A2（EphA2）和血管内皮生长因子（VEGF）在非小细胞肺癌中的表达及其意义。方法 用免疫组化SP法检测EphA2和VEGF在63例非小细胞肺癌中的表达情况。结果 在NSCLC中EphA2和VEGF呈高表达。EphA2的表达与NSCLC病理分型、分化程度无关，但是与临床分期及淋巴结转移密切相关。VEGF的表达与分化程度、淋巴结转移、临床分期有显著性差异。EphA2与VEGF表达呈正相关。结论 EphA2可与VEGF结合作为判断NSCLC恶性程度及预后的指标，及早期诊断指标和治疗的新靶点。

Expression and Significance of EphA2 and VEGF in Non-small Cell Lung Cancer

Objective To investigate the expression of EphA2 and VEGF in NSCLC and its significance. Methods The expression levels of EphA2 and VEGF were determined by immunohistochemical analysis in 63 cases of NSCLC. Results The expression of EphA2 and VEGF were significantly higher in NSCLC. EphA2 levels did not appear to relate to histological type or differentiation but did relate to clinical stage and metastases. Tumor differentiation, lymph node metastasis and clinical stage correlated with the expression of VEGF. EphA2 level positively correlated with VEGF level. Conclusion These data suggest that EphA2 may provide a molecular maker to identify and predict patients who have isolated brain metastases. Moreover, the high levels of EphA2 and VEGF in NSCLC may provide an opportunity for therapeutic targeting.